J 2019

Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative

SARIGIANNIS, Dimosthenis A., Spyros KARAKITSIOS, Elena DOMINGUEZ ROMERO, Krystalia PAPADAKI, Celine BROCHOT et. al.

Basic information

Original name

Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative

Authors

SARIGIANNIS, Dimosthenis A. (300 Greece), Spyros KARAKITSIOS (300 Greece), Elena DOMINGUEZ ROMERO (724 Spain, belonging to the institution), Krystalia PAPADAKI (300 Greece), Celine BROCHOT (250 France), Vikas KUMAR (724 Spain), Marta SCHUMACHER (724 Spain), Moustapha SY (276 Germany), Hans MIELKE (276 Germany), Mathias GREINER (276 Germany), Marcel MENGELERS (528 Netherlands) and Martin SCHERINGER (756 Switzerland, guarantor, belonging to the institution)

Edition

Environmental Research, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2019, 0013-9351

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30304 Public and environmental health

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.715

RIV identification code

RIV/00216224:14310/19:00110376

Organization unit

Faculty of Science

UT WoS

000468377500023

Keywords in English

PBTK modelling; Internal dose; Human biomonitoring; HBM4EU

Tags

Tags

International impact, Reviewed
Změněno: 24/3/2020 09:59, Mgr. Marie Šípková, DiS.

Abstract

V originále

Given the opportunities provided by internal dosimetry modelling in the interpretation of human biomonitoring (HBM) data, the assessment of the links between exposure to chemicals and observed HBM data can be effectively supported by PBTK modelling. This paper gives a comprehensive review of available human PBTK models for compounds selected as a priority by the European Human Biomonitoring Initiative (HBM4EU). We highlight their advantages and deficiencies and suggest steps for advanced internal dose modelling. The review of the available PBTK models highlighted the conceptual differences between older models compared to the ones developed recently, reflecting commensurate differences in research questions. Due to the lack of coordinated strategies for deriving useful biomonitoring data for toxicokinetic properties, significant problems in model parameterisation still remain; these are further increased by the lack of human toxicokinetic data due to ethics issues. Finally, questions arise as well as to the extent they are really representative of interindividual variability. QSARs for toxicokinetic properties is a complementary approach for PBTK model parameterisation, especially for data poor chemicals. This approach could be expanded to model chemico-biological interactions such as intestinal absorption and renal clearance; this could serve the development of more complex generic PBTK models that could be applied to newly derived chemicals. Another gap identified is the framework for mixture interaction terms among compounds that could eventually interact in metabolism. From the review it was concluded that efforts should be shifted toward the development of generic multi-compartmental and multi-route models, supported by targeted biomonitoring coupled with parameterisation by both QSAR approach and experimental (in-vivo and in-vitro) data for newly developed and data poor compounds.

Links

733032, interní kód MU
Name: European Human Biomonitoring Initiative (Acronym: HBM4EU)
Investor: European Union, Health, demographic change and wellbeing (Societal Challenges)